Evidence map›Paper›PMID 40723828›Full record

ReviewBiomolecules2025

Hepatic Lipoprotein Metabolism: Current and Future In Vitro Cell-Based Systems.

Izabella Kiss, Nicole Neuwert, Raimund Oberle, Markus Hengstschläger, Selma Osmanagic-Myers, Herbert Stangl

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Izabella KissInstitute of Medical Chemistry, Center for Pathobiochemistry and Genetics, Medical University Vienna, Vienna 1090, Austria.ORCID 0000-0003-1552-8716
Nicole NeuwertInstitute of Medical Chemistry, Center for Pathobiochemistry and Genetics, Medical University Vienna, Vienna 1090, Austria.
Raimund OberleInstitute of Medical Chemistry, Center for Pathobiochemistry and Genetics, Medical University Vienna, Vienna 1090, Austria.ORCID 0000-0001-6701-4130
Markus HengstschlägerInstitute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University Vienna, Vienna 1090, Austria.ORCID 0000-0002-3342-7583
Selma Osmanagic-MyersInstitute of Medical Chemistry, Center for Pathobiochemistry and Genetics, Medical University Vienna, Vienna 1090, Austria.ORCID 0000-0002-3834-1332
Herbert StanglInstitute of Medical Chemistry, Center for Pathobiochemistry and Genetics, Medical University Vienna, Vienna 1090, Austria.ORCID 0000-0002-7288-7320

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Changes in hepatic lipoprotein metabolism are responsible for the majority of metabolic dysfunction-associated disorders, including familial hypercholesterolemia (FH), metabolic syndrome (MetS), metabolic dysfunction-associated fatty liver disease (MAFLD), and age-related diseases such as atherosclerosis, a major health burden in modern society. This review aims to advance the understanding of state-of-the-art mechanistic concepts in lipoprotein metabolism, with a particular focus on lipoprotein uptake and secretion and their dysregulation in disease, and to provide a comprehensive overview of experimental models used to study these processes. Human lipoprotein research faces several challenges. First, significant differences in lipoprotein metabolism between humans and other species hinder the reliability of non-human model systems. Additionally, ethical constraints often limit studies on human lipoprotein metabolism using tracers. Lastly, while 2D hepatocyte cell culture systems are widely used, they are commonly of cancerous origins, limiting their physiological relevance and necessitating the use of more physiologically representative models. In this review, we will elaborate on key findings in lipoprotein metabolism, as well as limitations and challenges of currently available study tools, highlighting mechanistic insights throughout discussion of these models. These include human tracer studies, animal studies, 2D tissue culture-based systems derived from cancerous tissue as well as from induced pluripotent stem cells (iPSCs)/embryonic stem cells (ESCs). Finally, we will discuss precision-cut liver slices, liver-on-a-chip models, and, particularly, improved 3D models: (i) spheroids generated from either hepatoma cancer cell lines or primary human hepatocytes and (ii) organoids generated from liver tissues or iPSCs/ESCs. In the last section, we will explore future perspectives on liver-in-a-dish models in studying mechanisms of liver diseases, treatment options, and their applicability in precision medicine approaches. By comparing traditional and advanced models, this review will highlight the future directions of lipoprotein metabolism research, with a focus on the growing potential of 3D liver organoid models.

Indexed as

LipoproteinsLiverAnimalsHepatocytesHumansLipoproteinshumaniPSCs/ESCslipoproteinslivermetabolismorganoidstissue culture

Identifiers

PMID40723828
PMCPMC12292278

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.